Inovio Pharmaceuticals (INO) Interest Expenses (2011 - 2026)

Inovio Pharmaceuticals has reported Interest Expenses for 16 years, with the latest figure at $2.1 million in Q1 2026.

• Quarterly Interest Expenses fell 84.41% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 84.41% YoY) and the FY2025 annual result came in at $378.5 million, up 8.38% from the prior year.
• Interest Expenses fell to $2.1 million in Q1 2026 per INO's latest filing, from $13.7 million in the prior quarter.
• Over five years, Interest Expenses peaked at $13.7 million in Q1 2025 and troughed at -$167.0 in Q4 2024.
• A 5-year average of $1.6 million and a median of $423337.5 in 2022 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses sank 100.06% in 2024, then surged 2462.76% in 2025.
• Over 5 years, Interest Expenses stood at $733025.0 in 2022, then slumped by 63.58% to $266975.0 in 2023, then tumbled by 100.06% to -$167.0 in 2024, then surged by 8186926.35% to $13.7 million in 2025, then sank by 84.41% to $2.1 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $2.1 million, $13.7 million, and -$167.0 for Q1 2026, Q1 2025, and Q4 2024 respectively.